Cited by 147Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsClinical Laboratory Practices and Quality Control

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment.

Open access

Janelidze, Shorena, Pannee, Josef, Mikulskis, Alvydas, Chiao, Ping, Zetterberg, Henrik, Blennow, Kaj, Hansson, Oskar·2017·JAMA Neurology

DOI 10.1001/jamaneurol.2017.2814PMC PMC5822196

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Visual assessment of amyloid positron emission tomographic (PET) images has been approved by regulatory authorities for clinical use. Several immunoassays have been developed to measure β-amyloid (Aβ) 42 in cerebrospinal fluid (CSF). The agreement between CSF Aβ42 measures from different immunoassays and visual PET readings may influence the use of CSF biomarkers and/or amyloid PET assessment in clinical practice and trials. Objective: To determine the concordance between CSF Aβ42 levels measured using 5 different immunoassays and visual amyloid PET analysis. Design, Setting, and Participants: The study included 262 patients with mild cognitive impairment or subjective cognitive decline from the Swedish BioFINDER (Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably) cohort (recruited from September 1, 2010, through December 31, 2014) who had undergone flutemetamol F 18 ([18F]flutemetamol)-labeled PET. Levels of CSF Aβ42 were analyzed using the classic INNOTEST and the newer modified INNOTEST, fully automated Lumipulse (FL), EUROIMMUN (EI), and Meso Scale Discovery (MSD) assays. Concentrations of CSF Aβ were assessed using an antibody-independent mass spectrometry-based reference measurement procedure. Main Outcomes and Measures: The concordance of CSF Aβ42 levels and Aβ42:Aβ40 and Aβ42:tau ratios with visual [18F]flutemetamol PET status. Results: Of 262 participants (mean [SD] age, 70.9 [5.5] years), 108 were women (41.2%) and 154 were men (58.8%). The mass spectrometry-derived Aβ42 values showed higher correlations with the modified Aβ42-INNOTEST (r = 0.97), Aβ42-FL (r = 0.93), Aβ42-EI (r = 0.93), and Aβ42-MSD (r = 0.95) assays compared with the classic Aβ42-INNOTEST assay (r = 0.88; P ≤ .01). The signal in the classic Aβ42-INNOTEST assay was partly quenched by recombinant Aβ1-40 peptide. However, the classic Aβ42-INNOTEST assay showed better concordance with visual [18F]flutemetamol PET status (area under the receiver operating characteristic curve [AUC], 0.92) compared with the newer assays (AUCs, 0.87-0.89; P ≤ .01). The accuracies of the newer assays improved significantly when Aβ42:Aβ40 (AUCs, 0.93-0.95; P ≤ .01), Aβ42 to total tau (T-tau) (AUCs, 0.94; P ≤ .05), or Aβ42 to phosphorylated tau (P-tau) (AUCs, 0.94-0.95; P ≤ .001) ratios were used. A combination of the Aβ42:Aβ40 ratio and T-tau or P-tau level did not improve the accuracy compared with the ratio alone. Conclusions and Relevance: Concentrations of CSF Aβ42 derived from the new immunoassays (modified INNOTEST, FL, EI, and MSD) may correlate better with the antibody-independent mass spectrometry-based reference measurement procedure and may show improved agreement with visual [18F]flutemetamol PET assessment when using the Aβ42:Aβ40 or Aβ42:tau ratios. These findings suggest the benefit of implementing the CSF Aβ42:Aβ40 or Aβ42:tau ratios as a biomarker of amyloid deposition in clinical practice and trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2017.2814

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Practical Statistics for Medical Research.
Bartko, J. J., & Altman, D. G. (1992) · Journal of the American Statistical Association · doi:10.2307/2290246 · Cited by 4,834
Comparing correlated correlation coefficients
Meng, X.-L., Rosenthal, R., & Rubin, D. B. (1992) · Psychological Bulletin · doi:10.1037/0033-2909.111.1.172 · Cited by 2,472
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citation
mixtools : An R Package for Analyzing Finite Mixture Models
Benaglia, T., Chauveau, D., Hunter, D. R., & Young, D. S. (2009) · Journal of Statistical Software · doi:10.18637/jss.v032.i06 · Cited by 1,391
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664

Show all 36 references

Research works printed but not linked: 1

Janelidze S, Zetterberg H, Mattsson N, et al; Swedish BioFINDER study group. CSF Aβ42:Aβ40 and Aβ42:Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3 (3):154-165.

Sorted by citations

The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0485-0 · Cited by 585
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15436-0 · Cited by 450
Self-citation
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353
The complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 343
Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease
Berron, D., van Westen, D., Ossenkoppele, R., Strandberg, O. T., & Hansson, O. (2020) · Brain · doi:10.1093/brain/awaa068 · Cited by 310
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cicognola, C., Janelidze, S., Hertze, J., Zetterberg, H., Blennow, K., Mattsson, N., & Hansson, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00804-9 · Cited by 324
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
Leuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgren, N., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0989 · Cited by 222
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Alcolea, D., Pegueroles, J., Muñoz, L., Camacho, V., López‐Mora, D., Fernández‐León, A., Le Bastard, N., Huyck, E., Nadal, A., Olmedo, V., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50873 · Cited by 183
Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
Blennow, K., Shaw, L. M. J., Stomrud, E., Mattsson, N., Toledo, J. B., Buck, K., Wahl, S., Eichenlaub, U., Lifke, V., Simon, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54204-z · Cited by 194
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau
Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12395 · Cited by 188
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
Palmqvist, S., Stomrud, E., Cullen, N. C., Janelidze, S., Manuilova, E., Jethwa, A., Bittner, T., Eichenlaub, U., Suridjan, I., Kollmorgen, G., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12751 · Cited by 166
Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease
Leitão, M. J., Silva‐Spínola, A., Santana, I. J., Olmedo, V., Nadal, A., Bastard, N. L., & Baldeiras, I. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0550-8 · Cited by 164
Cognitive effects of Lewy body pathology in clinically unimpaired individuals
Palmqvist, S., Rossi, M., Hall, S., Quadalti, C., Mattsson, N., Dellavalle, S., Tideman, P., Pereira, J. B., Nilsson, M. H., Mammana, A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02450-0 · Cited by 165
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 163
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136
Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170680 · Cited by 137
Blood-based biomarkers for Alzheimer’s disease—An update
Zetterberg, H. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.025 · Cited by 128
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment
Baldeiras, I., Santana, I. J., Leitão, M. J., Gens, H., Pascoal, R., Tábuas‐Pereira, M., Beato-Coelho, J., Duro, D., Almeida, M. R., & Oliveira, C. R. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0362-2 · Cited by 123
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease
Alawode, D. O. T., Heslegrave, A., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O’Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13332 · Cited by 107
A brief history of “Alzheimer disease”
Knopman, D. S., Petersen, R. C., & Jack, C. R. (2019) · Neurology · doi:10.1212/wnl.0000000000007583 · Cited by 104
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109
Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy
Grothe, M. J., Moscoso, A., Ashton, N. J., Karikari, T. K., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., Schöll, M., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012513 · Cited by 99
MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study
ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S. J., Vandenberghe, R., Gabel, S., Schaeverbeke, J., Scheltens, P., Blin, O., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0428-1 · Cited by 78
Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
Cullen, N. C., Janelidze, S., Mattsson, N., Palmqvist, S., Bittner, T., Suridjan, I., Jethwa, A., Kollmorgen, G., Brum, W. S., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12706 · Cited by 85
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe
Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 87
Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease
Shaw, L. M. J., Waligórska, T., Fields, L., Korecka, M., Figurski, M., Trojanowski, J. Q., Eichenlaub, U., Wahl, S., Quan, M., Pontecorvo, M. J., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.002 · Cited by 81
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 87
Mass spectrometry‐based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids
Korecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 82
Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease
Guo, T., Korman, D., Joie, R. L., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00665-8 · Cited by 67
Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
Willemse, E. A. J., Tijms, B. M., van Berckel, B. N. M., Bastard, N. L., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12182 · Cited by 62
Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00696-1 · Cited by 62
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
Stockmann, J., Verberk, I. M. W., Timmesfeld, N., Denz, R., Budde, B., Lange-Leifhelm, J., Scheltens, P., van der Flier, W. M., Nabers, A., Teunissen, C. E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00738-8 · Cited by 62
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 78
Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature
Zetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 59
Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort
Orellana, A., García‐González, P., Valero, S., Montrreal, L., de Rojas, I., Hernández, I., Rosende‐Roca, M., Vargas, L., Tartari, J. P., Antonio, E. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136891 · Cited by 57
Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals
Ingala, S., Tomassen, J., Collij, L. E., Prent, N., Ent, D. V. ‘., ten Kate, M., Konijnenberg, E., Yaqub, M. M., Scheltens, P., de Geus, E. J. C., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab201 · Cited by 65
Alzheimer disease biomarkers: moving from CSF to plasma for reliable detection of amyloid and tau pathology
Kang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
Teunissen, C. E., Otto, M., Engelborghs, S., Herukka, S., Lehmann, S., Lewczuk, P., Lleó, A., Perret‐Liaudet, A., Tumani, H., Turner, M. R., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0359-x · Cited by 56
Towards a unified protocol for handling of CSF before β-amyloid measurements
Janelidze, S., Stomrud, E., Brix, B., & Hansson, O. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0517-9 · Cited by 54
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
de Wilde, A., Reimand, J., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., Bouwman, F. H., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0532-x · Cited by 54
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Leuzy, A., Rakêt, L. L., Villemagne, V. L., Klein, G., Tonietto, M., Olafson, E., Baker, S. L., Saad, Z. S., Bullich, S., Lopresti, B. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13908 · Cited by 53
Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults
Guo, T., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010596 · Cited by 51
Antemortem CSF A β 42/A β 40 ratio predicts Alzheimer's disease pathology better than A β 42 in rapidly progressive dementias
Baiardi, S., Abu‐Rumeileh, S., Rossi, M., Zenesini, C., Bartoletti‐Stella, A., Polischi, B., Capellari, S., & Parchi, P. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.697 · Cited by 53
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
Keshavan, A., Wellington, H., Chen, Z., Khatun, A., Chapman, M. D., Hart, M., Cash, D. M., Coath, W., Parker, T. D., Buchanan, S. M., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12131 · Cited by 49
Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease
Liu, L., Lauro, B. M., He, A., Lee, H., Bhattarai, S., Wolfe, M. S., Bennett, D. A., Karch, C. M. M., Young‐Pearse, T. L., Dominantly Inherited Alzheimer Network (DIAN), et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12646 · Cited by 45
Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer’s disease: Where do we stand?
Veerabhadrappa, B., Delaby, C., Hirtz, C., Vialaret, J., Alcolea, D. A., Lleó, A., Fortea, J., Santosh, M. S., Choubey, S., & Lehmann, S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1678011 · Cited by 49
CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
Constantinides, V. C., Paraskevas, G. P., Boufidou, F., Bourbouli, M., Pyrgelis, E.-S., Stefanis, L., & Kapaki, E. N. (2023) · Diagnostics · doi:10.3390/diagnostics13040783 · Cited by 53
Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic
Müller, E. G., Edwin, T. H., Stokke, C., Navelsaker, S. S., Babovic, A., Bogdanović, N., Knapskog, A., & Revheim, M. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221365 · Cited by 48
Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest
Dakterzada, F., Ortega, R. L., Arias, A. M., Llena, I. R., Ruiz-Julián, M., Huerto, R. P., Tahan, N., & Piñol‐Ripoll, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.604119 · Cited by 47
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: a multi-cohort study
Salvadó, G., Larsson, V., Cody, K. A., Cullen, N. C., Jonaitis, E. M., Stomrud, E., Kollmorgen, G., Wild, N., Palmqvist, S., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12907 · Cited by 46
Self-citation
Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis
Agnello, L., Piccoli, T., Vidali, M., Cuffaro, L., Sasso, B. L., Iacolino, G., Giglio, R. V., Lupo, F., Alongi, P., Bivona, G., et al. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1740939 · Cited by 46
A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer’s Disease
Xu, C., Zhao, L., & Dong, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220673 · Cited by 46
Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
Yamashita, K., Miura, M., Watanabe, S., Ishiki, K., Arimatsu, Y., Kawahira, J., Kubo, T., Sasaki, K., Arai, T., Hagino, K., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01029-0 · Cited by 44
Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age
Ayton, S., Janelidze, S., Roberts, B. R., Palmqvist, S., Kalinowski, P., Diouf, I., Belaidi, A. A., Stomrud, E., Bush, A. I., & Hansson, O. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101904 · Cited by 43
Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period
Glans, I., Sonestedt, E., Nägga, K., Gustavsson, A.-M., González-Padilla, E., Borne, Y., Stomrud, E., Melander, O., Nilsson, P. M., Palmqvist, S., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000201336 · Cited by 40
2023 China Alzheimer’s disease: facts and figures
Xiao, J., Li, J., Wang, J., Zhang, X., Wang, C., Peng, G., Hu, H., Liu, H., Liu, J., Shen, L., et al. (2023) · Human Brain · doi:10.37819/hb.3.1771 · Cited by 41
18F-Flortaucipir in TDP-43 associated frontotemporal dementia
Smith, R., Santillo, A. F., Waldö, M. L., Strandberg, O., Berron, D., Vestberg, S., van Westen, D., van Swieten, J., Honer, M., & Hansson, O. (2019) · Scientific Reports · doi:10.1038/s41598-019-42625-9 · Cited by 33
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis
Paciotti, S., Sepe, F. N., Eusebi, P., Farotti, L., Cataldi, S., Gatticchi, L., & Parnetti, L. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.03.1612 · Cited by 26
Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans
Moon, S., Kim, S., Mankhong, S., Choi, S. H., Vandijck, M. L. J., Kostanjevečki, V., Jeong, J. H., Yoon, S. J., Park, K. W., Kim, E. J., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00767-3 · Cited by 28
Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
Kirsebom, B., Nordengen, K., Selnes, P., Waterloo, K. K., Torsetnes, S. B., Gísladóttir, B., Brix, B., Vanmechelen, E., Bråthen, G., Hessen, E., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.003 · Cited by 27
Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases
Lindström, E., Oddstig, J., Danfors, T., Jögi, J., Hansson, O., & Lubberink, M. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102386 · Cited by 26
Onset of Preclinical Alzheimer Disease in Monozygotic Twins
Konijnenberg, E., Tomassen, J., den Braber, A., ten Kate, M., Yaqub, M. M., Mulder, S. D., Nivard, M. G., Vanderstichele, H., Lammertsma, A. A., Teunissen, C. E., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26048 · Cited by 25
Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC–MS/MS Reference Method
Korecka, M., Figurski, M., Landau, S. M., Brylska, M., Alexander, J., Blennow, K., Zetterberg, H., Jagust, W., Trojanowski, J. Q., Shaw, L. M. J., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa012 · Cited by 25
Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort
Santos, L. E., Mattos, P., Pinheiro, T., Silva, A., Drummond, C., Sudo, F. K., Barros‐Aragão, F. G. Q., Vanderborght, B., Brandão, C. O., Ferreira, S. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56756-3 · Cited by 28
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
Keshavan, A., Wellington, H., Chen, Z., Khatun, A., Chapman, M. D., Hart, M., Cash, D. M., Coath, W., Parker, T. D., Buchanan, S. M., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12097 · Cited by 24
The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People
Nilsson, M. H., Tangen, G. G., Palmqvist, S., van Westen, D., Mattsson, N., Stomrud, E., & Hansson, O. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa143 · Cited by 25
Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum
Chen, Y.-H., Lin, R.-R., Huang, H.-F., Xue, Y., & Tao, Q. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.848180 · Cited by 25
Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
Aichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00828-1 · Cited by 23
Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease
Yener, G., Gündüz, D. H., Yıldırım, E., Aktürk, T., Başar‐Eroğlu, C., Bonanni, L., Percio, C. D., Farina, F. R., Ferri, R., Güntekin, B., et al. (2022) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2022.05.008 · Cited by 21
Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases
Brinkmalm, A., Portelius, E., Brinkmalm, G., Pannee, J., Dahlén, R., Gobom, J., Blennow, K., & Zetterberg, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14594 · Cited by 23
An automated clinical mass spectrometric method for identification and quantification of variant and wild‐type amyloid‐β 1‐40 and 1‐42 peptides in CSF
DeMarco, M. L., Nguyen, Q., Fok, A., Hsiung, G. R., & van der Gugten, J. G. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12036 · Cited by 19
The CORCOBIA study: Cut-off points of Alzheimer’s disease CSF biomarkers in a clinical cohort
Puig‐Pijoan, A., García‐Escobar, G., Fernández‐Lebrero, A., Manero-Borràs, R. M., Sánchez‐Benavides, G., Navalpotro‐Gómez, I., Cascales‐Lahoz, D., Suárez‐Calvet, M., Grau‐Rivera, O., Boltes, A., et al. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2022.05.002 · Cited by 19
Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects
Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 19
Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers
Lowe, V. J., Mester, C. T., Lundt, E. S., Lee, J., Ghatamaneni, S., Algeciras‐Schimnich, A., Campbell, M. R., Graff‐Radford, J., Nguyen, A. T., Min, H.-K. P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14317 · Cited by 20
Protein fibril length in cerebrospinal fluid is increased in Alzheimer’s disease
Nirmalraj, P. N., Schneider, T. R., Lüder, L., & Felbecker, A. (2023) · Communications Biology · doi:10.1038/s42003-023-04606-7 · Cited by 17
Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer’s Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms
Dakterzada, F., Cipriani, R., Ortega, R. L., Arias, A. M., Llena, I. R., Ruiz-Julián, M., Huerto, R. P., Tahan, N., Matute, C., Capetillo‐Zarate, E., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094594 · Cited by 17
CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti‐tau antibody semorinemab
Sandoval, C., Lee, J., Toth, B., Nagaraj, R., Schauer, S. P., Hoffman, J. C., Calderon, E., Kollmorgen, G., Bohorquez, S. M. S., Monteiro, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14271 · Cited by 18
Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease
Hansson, K., Dahlén, R., Hansson, O., Pernevik, E., Paterson, R. W., Schott, J. M., Magdalinou, N. K., Zetterberg, H., Blennow, K., & Gobom, J. (2019) · Clinical mass spectrometry · doi:10.1016/j.clinms.2019.07.002 · Cited by 15
Dissociation of cerebrospinal fluid amyloid-β and tau levels in patients with prolonged posttraumatic disorders of consciousness
Bagnato, S., Andriolo, M., Boccagni, C., Santangelo, A., D’Ippolito, M. E., & Galardi, G. (2018) · Brain Injury · doi:10.1080/02699052.2018.1479042 · Cited by 15
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
Bellomo, G., Cataldi, S., Paciotti, S., Paoletti, F. P., Chiasserini, D., & Parnetti, L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00689-0 · Cited by 15
β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns
Jiang, C., Wang, Q., Xie, S., Chen, Z., Fu, L., Peng, Q., Liang, Y., Guo, H., Guo, T., & Initiative, A. D. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac084 · Cited by 14
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
de Bruin, H., Groot, C., Barthel, H., Bischof, G. N., Blazhenets, G., Boellaard, R., Boon, B. D. C., Brendel, M., Cash, D. M., Coath, W., et al. (2025) · Brain · doi:10.1093/brain/awaf279 · Cited by 13
Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
Motta, C., Donna, M. G. D., Bonomi, C. G., Assogna, M., Chiaravalloti, A., Mercuri, N. B., Koch, G., & Martorana, A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01291-w · Cited by 11
Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease
Arnold, S. E., Hendrix, S. B., Nicodemus‐Johnson, J., Knowlton, N., Williams, V. J., Burns, J. M., Crane, M. K., McManus, A. J., Vaishnavi, S., Arvanitakis, Z., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12487 · Cited by 10
Preclinical Alzheimer’s Disease: Implications for Refinement of the Concept
Vos, S. J. B., & Visser, P. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179943 · Cited by 12
Association of plasma β-amyloid 40 and 42 concentration with type 2 diabetes among Chinese adults
Peng, X., Xu, Z., Mo, X., Guo, Q., Yin, J., Xu, M., Peng, Z., Sun, T., Zhou, L., Peng, X., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05102-x · Cited by 10
How far is the goal of applying β-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer’s disease with standardization of measurements?
Zou, Y., Yu, S., Ma, X., Ma, C., Mao, C., Mu, D., Li, L., Gao, J., & Qiu, L. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.11.013 · Cited by 9
Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity
Chun, M. Y., Jang, H., Kim, H. J., Kim, J. P., Gallacher, J., Allué, J. A., Sarasa, L., Castillo, S., Pascual‐Lucas, M., Na, D. L., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1126799 · Cited by 9
Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand
Tippett, L. J., Cawston, E. E., Morgan, C., Melzer, T. R., Brickell, K. L., Ilse, C., Cheung, G., Kirk, I. J., Roberts, R. P., Govender, J., et al. (2022) · Journal of the Royal Society of New Zealand · doi:10.1080/03036758.2022.2098780 · Cited by 8
Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network
Pavlik, V. N., for the CONCORD-AD investigators, Burnham, S. C., Kass, J. S., Helmer, C., Palmqvist, S., Vassilaki, M., Dartigues, J., Hansson, O., Masters, C. L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210525 · Cited by 8
Use of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic
Stiffel, M., Bergeron, D., Amari, K. M., Poulin, É., Roberge, X., Meilleur‐Durand, S., Sellami, L., Molin, P., Nadeau, Y., Fortin, M., et al. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.67 · Cited by 9
Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes
Pyun, J., Park, Y. H., Kang, M. J., & Kim, S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01580-y · Cited by 6
Estudio CORCOBIA: determinación de puntos de corte de biomarcadores de enfermedad de Alzheimer en LCR en una cohorte clínica
Puig‐Pijoan, A., García‐Escobar, G., Fernández‐Lebrero, A., Borràs, R. M. M., Sánchez‐Benavides, G., Navalpotro‐Gómez, I., Cascales‐Lahoz, D., Suárez‐Calvet, M., Grau‐Rivera, O., Boltes, A., et al. (2022) · Neurología · doi:10.1016/j.nrl.2022.05.005 · Cited by 6
Blood‐based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider
Zetterberg, H., Apostolova, L. G., & Snyder, P. J. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.10.001 · Cited by 6
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations
Petersen, R. C., Graf, A., Brady, C., Santi, S. D., Florian, H., Landen, J. W., Pontecorvo, M., RANDOLPH, C. C., Sink, K. M., Carrillo, M. C., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12434 · Cited by 4
Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity
Pyun, J., Park, Y. H., Youn, Y. C., Kang, M. J., Shim, K. H., Jang, J., You, J., Nho, K. T., Kim, S., Initiative, T. A. D. N., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02766-6 · Cited by 7

Authors: Janelidze, S., Pannee, J., Mikulskis, A., Chiao, P., Zetterberg, H., Blennow, K., & Hansson, O.
Affiliations: Lund University (SE)
University of Gothenburg (SE)
Biogen (United States) (US)
Sahlgrenska University Hospital (SE)
Corresponding author: Janelidze, Shorena
ORCID: Janelidze, Shorena
Pannee, Josef
Zetterberg, Henrik
Blennow, Kaj
Hansson, Oskar
Venue: JAMA Neurology
Publisher: American Medical Association (AMA)
Published: 2017-12-01
Volume: 74
Issue: 12
Pages: 1492
ISSN: 2168-6149 (ISSN-L)
DOI: 10.1001/jamaneurol.2017.2814
PMC: PMC5822196
OpenAlex: W2767595531
Cited by: 147
References: 36
Citations by year: 2026: 9 · 2025: 13 · 2024: 19 · 2023: 13 · 2022: 19 · 2021: 24 · 2020: 23 · 2019: 15 · 2018: 12
FWCI: 11.24
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Neurology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Lund University Publications (Lund University) (submittedVersion)
Funders: Australian Government
Vetenskapsrådet
Fujirebio Europe
Marcus och Amalia Wallenbergs minnesfond
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
Keywords: amyloid PET, amyloid-beta 42, cerebrospinal fluid biomarkers, 18F-flutemetamol, Meso Scale Discovery, Aβ42/Aβ40 ratio, mild cognitive impairment
MeSH terms: Aged, Amyloid, Aniline Compounds, Cerebral Cortex, Female, Humans, Immunoassay, Male, Peptide Fragments, ROC Curve, Sweden, Cohort Studies, Amyloid beta-Peptides, tau Proteins, Radiopharmaceuticals, Area Under Curve, Positron-Emission Tomography, Benzothiazoles, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks